{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05405595",
            "orgStudyIdInfo": {
                "id": "ADG126-P001"
            },
            "secondaryIdInfos": [
                {
                    "id": "KEYNOTE-C98, MK-3475-C98",
                    "type": "OTHER",
                    "domain": "Merck Sharp & Dohme LLC"
                }
            ],
            "organization": {
                "fullName": "Adagene Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors",
            "officialTitle": "A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-combination-with-pembrolizumab-in-patients-with-advanced-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-16",
            "studyFirstSubmitQcDate": "2022-06-02",
            "studyFirstPostDateStruct": {
                "date": "2022-06-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Adagene Inc",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.",
            "detailedDescription": "This is a Phase 1b/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of ADG126-Pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.\n\nStudy drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody)."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced/Metastatic Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 131,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ADG126 in combination with Pembrolizumab (Trade name KEYTRUDA\u00ae)",
                    "type": "EXPERIMENTAL",
                    "description": "An IV infusion of ADG126 over 60-90 minutes will be administered 30-60 minutes after administration of pembrolizumab (KEYTRUDA\u00ae) infusion. A treatment cycle will consist of 21 days.",
                    "interventionNames": [
                        "Drug: ADG126"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ADG126",
                    "description": "ADG126 and Pembrolizumab (KEYTRUDA\u00ae) combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.",
                    "armGroupLabels": [
                        "ADG126 in combination with Pembrolizumab (Trade name KEYTRUDA\u00ae)"
                    ],
                    "otherNames": [
                        "Pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.",
                    "description": "Number of participants experiencing maximum tolerated dose (MTD) in dose escalation levels",
                    "timeFrame": "9 months"
                },
                {
                    "measure": "the safety and tolerability of ADG126 at escalating dose level in combination with pembrolizumab in adults with advanced metastatic solid tumors",
                    "description": "Number of participants with adverse events as assessed by CTCAE v5.0",
                    "timeFrame": "9 months"
                },
                {
                    "measure": "Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimens",
                    "description": "Number of Participants with preliminary antitumor activity",
                    "timeFrame": "9 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetic (PK) profile/parameters",
                    "description": "Area under the time concentration curve (AUC) from time zero to infinity (AUC0-inf)",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "Maximum (peak) plasma concentration (Cmax)",
                    "description": "Maximum (peak) plasma concentration (Cmax)",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "Time to maximum (peak) concentration (Tmax)",
                    "description": "Time to maximum (peak) concentration (Tmax)",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "Trough concentration (Ctrough)",
                    "description": "Trough concentration (Ctrough)",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "Incidence of ADAs",
                    "description": "this will be summarized for all patients who received at least 1 administration of ADG126. efficacy and safety will be evaluated.",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "To assess the disease control rate (DCR)",
                    "description": "this will be calculated as the proportion/percentage of patients with best overall response of CR,PR,SD or progressive disease will be calculated.",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "To assess the progression free survival (PFS)",
                    "description": "PFS will be censored at the time of the last evaluable tumor assessment (RECISTv1.1 and /or iRECIST)",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                },
                {
                    "measure": "To assess the overall survival (OS)",
                    "description": "this will be used to estimate median survival times where applicable.",
                    "timeFrame": "From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. \u226518 years of age at the time of informed consent.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n3. Wash out period from previous antitumor therapies\n4. At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.\n5. Adequate organ function.\n6. An archival tumor biopsy is required and should be taken within 2 years of enrollment. If not available, a fresh tumor biopsy is acceptable.\n7. For Dose Escalation Phase Only: Patients with advanced or metastatic solid tumors, histologically or pathologically confirmed, who have progressed after all standard therapies, or for whom no further standard therapy exists.\n\n   Dose Expansion Phase Only: Tumor tissues (archived or fresh biopsy) before treatment are required for all patients. Biopsies and tumor tissues after treatment are optional but preferred for patients with MSS-CRC and 2L anti-PD-1/anti-PD-L1 experienced NSCLC.\n8. No prior immunotherapy\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding females.\n2. Childbearing potential who does not agree to the use of contraception during the treatment period.\n3. Treatment with any investigational drug within washout period.\n4. Prior treatment with an anti-CTLA-4 therapy.\n5. History of significant immune-mediated AE.\n6. Central nervous system (CNS) disease involvement.\n7. History or risk of autoimmune disease.\n8. Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (\\>10 mg/day prednisone or equivalent).\n9. Any uncontrolled active infections requiring systemic antimicrobial treatment (viral, bacterial, or other), or uncontrolled or poorly controlled, asthma, chronic obstructive pulmonary disease (COPD).\n10. Major surgery within 4 weeks prior to the first dose of the study drug.\n11. Has had an allogeneic tissue/solid organ transplant.\n12. Has received a COVID-19 vaccine within 7 days prior to the first dose of study treatment. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Administration of killed vaccines are allowed.\n13. A positive COVID-19 test within 14 days of Cycle 1 Day 1.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Xiaohong She, MS",
                    "role": "CONTACT",
                    "phone": "408-838-9296",
                    "email": "kristine_she@adagene.com"
                },
                {
                    "name": "Jiping Zha, MD, PhD",
                    "role": "CONTACT",
                    "phone": "650-785-9347",
                    "email": "jiping_zha@adagene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jiping Zha, MD, PhD",
                    "affiliation": "Adagene Inc",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "HonorHealth Research Institute",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85251",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharma Sunil, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "City of Hope National Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Daneng Li, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Florida cancer specialist",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Patel Manish, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Rami Guy",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Dong -A University Hospital",
                    "status": "RECRUITING",
                    "city": "Seogu",
                    "state": "Busan Gwangyeogsi",
                    "zip": "49201",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Sung Yong Oh, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Grami Dong",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.74484,
                        "lon": 127.13739
                    }
                },
                {
                    "facility": "Chungbuk National University Hospital",
                    "status": "RECRUITING",
                    "city": "Cheongju-si",
                    "state": "Chungcheongbugdo",
                    "zip": "28644",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Ki Hyeong Lee, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Seul gi Gong",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.63722,
                        "lon": 127.48972
                    }
                },
                {
                    "facility": "CHA Bundang Medical Center, CHA university",
                    "status": "RECRUITING",
                    "city": "Seongnam",
                    "state": "Gyeonggido",
                    "zip": "13496",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Hing Jae Chon, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Song I Kang",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.43861,
                        "lon": 127.13778
                    }
                },
                {
                    "facility": "The Catholic University of Korea Street. Vincent Hospital",
                    "status": "RECRUITING",
                    "city": "Suwon",
                    "state": "Gyeonggido",
                    "zip": "16247",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Yun Gyoo Lee, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.29111,
                        "lon": 127.00889
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Byoung Yong Shim, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Keimyung University Dongsan Hospital",
                    "status": "RECRUITING",
                    "city": "Daegu",
                    "zip": "41931",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Keon Uk Park, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Ehyun Choi",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.87028,
                        "lon": 128.59111
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Seock -Ah Im, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Kim Ji Won",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "KangBuk Samsung Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03081",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Yun Gyoo Lee, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Sun Young Kim, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Ko Eun- Young",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "3722",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Sang Joon Shin, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Da Seul Lee",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}